The panel can detect and differentiate SARS-CoV-2 and 20 other pathogens known to cause serious respiratory disease from nasopharyngeal swabs in symptomatic patients.
Thermo Fisher plans to use the proceeds to pay in part for the acquisition of Qiagen, expected to close in the first half of 2021, and for general corporate purposes.
The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.
According to the recall, initiated on Jan. 28, a glitch in the software’s data reporting to LIM systems could cause false-negative results from PCR assays running on the instrument.
The panel will aid in the diagnosis of patients with respiratory symptoms in about an hour by differentiating SARS-CoV-2 from other bacterial and viral pathogens.
